全文获取类型
收费全文 | 111836篇 |
免费 | 10058篇 |
国内免费 | 3145篇 |
专业分类
耳鼻咽喉 | 916篇 |
儿科学 | 3410篇 |
妇产科学 | 1443篇 |
基础医学 | 7287篇 |
口腔科学 | 1462篇 |
临床医学 | 15635篇 |
内科学 | 19696篇 |
皮肤病学 | 1033篇 |
神经病学 | 5772篇 |
特种医学 | 4402篇 |
外国民族医学 | 3篇 |
外科学 | 14570篇 |
综合类 | 19033篇 |
现状与发展 | 4篇 |
预防医学 | 9717篇 |
眼科学 | 1262篇 |
药学 | 10054篇 |
142篇 | |
中国医学 | 5819篇 |
肿瘤学 | 3379篇 |
出版年
2024年 | 148篇 |
2023年 | 2079篇 |
2022年 | 3499篇 |
2021年 | 5569篇 |
2020年 | 5528篇 |
2019年 | 4699篇 |
2018年 | 4501篇 |
2017年 | 4495篇 |
2016年 | 4376篇 |
2015年 | 4037篇 |
2014年 | 7887篇 |
2013年 | 7711篇 |
2012年 | 6545篇 |
2011年 | 6846篇 |
2010年 | 5582篇 |
2009年 | 5389篇 |
2008年 | 5357篇 |
2007年 | 5592篇 |
2006年 | 4710篇 |
2005年 | 4093篇 |
2004年 | 3281篇 |
2003年 | 2869篇 |
2002年 | 2294篇 |
2001年 | 2182篇 |
2000年 | 1746篇 |
1999年 | 1506篇 |
1998年 | 1224篇 |
1997年 | 1122篇 |
1996年 | 977篇 |
1995年 | 1086篇 |
1994年 | 990篇 |
1993年 | 760篇 |
1992年 | 861篇 |
1991年 | 679篇 |
1990年 | 579篇 |
1989年 | 502篇 |
1988年 | 509篇 |
1987年 | 440篇 |
1986年 | 341篇 |
1985年 | 358篇 |
1984年 | 350篇 |
1983年 | 216篇 |
1982年 | 280篇 |
1981年 | 207篇 |
1980年 | 195篇 |
1979年 | 170篇 |
1978年 | 168篇 |
1977年 | 110篇 |
1976年 | 115篇 |
1975年 | 73篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
4.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
5.
6.
目的了解不同机种军事飞行员运动心肺功能有无差异。方法飞行员分为高性能战斗机和普通战斗机两组,采用意大利COSMED运动心肺功能测试仪,选择自行车功率计运动方式,以25 W/min功率递增速率极量运动方案,进行运动心肺功能测试,比较两组运动心肺功能数据的主要指标。结果两组飞行员各207例完成运动心肺功能测试,两组的年龄、身高、体质量和体质量指数差异均无统计学意义(P均>0.05)。两组数据的主要指标中,除了峰值氧脉搏[高性能战斗机组(15.36±2.43)mL/bpm,普通战斗机组(14.95±2.13)mL/bpm]差异有统计学意义(P=0.038),其他差异均无统计学意义,而且各指标差异幅度均较小,高性能战斗机飞行员组的峰值氧脉搏高于普通战斗机组2.74%。结论综合比较,高性能战斗机和普通战斗机飞行员的运动心肺功能无明显差异,提示两组飞行员日常有氧运动训练效果一致,在转换飞行机种时,可以不受运动心肺功能的限制。 相似文献
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(12):1531-1535
This study investigated the role of dual-energy computed tomography (CT) for lesion characterization in patients with peripheral arterial disease manifesting with chronic total occlusions (CTOs). Forty-one symptomatic patients with CTOs underwent dual-energy CT angiography before endovascular treatment. The lesions were subsequently analyzed in a dedicated workstation, and 2 indexes—dual-energy index (DEI) and effective Z (Zeff)—were calculated, ranging from 0.0027 to 0.321 and from 6.89 to 13.02, respectively. Statistical analysis showed a significant correlation between the DEI and Zeff values (P < .001). The interobserver intraclass correlation coefficient was 0.91 for the mean Zeff values and 0.86 for the mean DEI values. This technique could potentially provide useful information regarding the composition of a CTO. 相似文献
8.
9.
《Revista brasileira de otorrinolaringologia (English ed.)》2022,88(4):621-624
ObjectivesRecurrent Aphthous Stomatitis (RAS) a chronic idiopathic oral mucosal disease. But yet the etiology and pathogenesis of RAS are not exactly known, it is thought that inflammation play an important role in the pathogenesis. The aim of this study is to demonstrate the role of systemic inflammation among the possible etiological factors of RAS and to find the possible diagnostic correlation between Systemic Immune Inflammation Index (SII).MethodsPatients who were consulted the otolaryngology outpatient clinic and diagnosed with RAS between 2019–2021 were retrospectively analyzed. Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR) and SII values were calculated based on the results of complete blood count. Demographic and hematological parameters between control and RAS groups were compared. The statistical significance level was considered as <0.05.ResultsThere was no statistically significant difference between the control and RAS groups in terms of sex and age distributions (p = 0.566 and p = 0.173, respectively). SII, NLR and PLR values were significantly higher in the RAS group compared to the controls (p < 0.001, p < 0.001 and p = 0.001, respectively). A very strong correlation between SII and NLR, moderately strong correlation between SII and PLR and moderate correlation between NLR and PLR values were detected (respectively ρ: 0.813, 0.719, 0.532; p-values <0.001).ConclusionSII, NLR and PLR has significantly higher levels in the RAS group compared to the control group, that it supports the role of systemic inflammation in the etiopathogenesis of RAS. In addition, the results show that SII is a valuable marker for inflammation.Level of evidence4. 相似文献
10.
《Clinical microbiology and infection》2022,28(8):1120-1125
ObjectivesOur aim was to evaluate the effect of the updated European Organization for Research and Treatment of Cancer (EORTC) and Mycoses Study Group 2019 definitions for invasive pulmonary aspergillosis (IPA) on patient classification and the related all-cause 12-week mortality.MethodsIn this retrospective cohort study from our tertiary care centre, we reclassified patients with haematological malignancy who underwent bronchoalveolar lavage between 2014 and 2019 for suspected IPA using the novel EORTC 2019 criteria. We performed receiver operating characteristic curve analysis to define the optimal cut-off for positive PCR and galactomannan and present survival analyses and their possible association with these diagnostic criteria through post hoc comparisons with log rank and Cox regression.ResultsFrom 323 episodes of suspected IPA in 282 patients, 73 were reclassified: 31 (42.5%) from possible to probable IPA, 5 (6.8%) from EORTC criteria not met to probable IPA, and 37 (50.7%) from EORTC criteria not met to possible IPA. Probable IPA increased therefore 11.1% (64/323, 19.8% to 100/323, 30.9%), mostly due to positive PCR (31/36, 86.1%). There was no difference in mortality between newly defined possible and probable IPA (log rank p = 0.950). Mortality was higher in probable cases with lower cycle thresholds (Ct values) versus higher Ct values (p = 0.004). Receiver operating characteristic curve analysis showed an optimal Ct value cut-off of 36.8 with a sensitivity of 75% (95% CI 64.9%–85.1%) and a specificity of 61.7% (95% CI 53.5–69.9) for 12-week mortality.DiscussionThe new EORTC criteria led to 11.1% more probable IPA diagnoses, mostly due to Aspergillus PCR. Restricting positive PCR to below a certain threshold might improve the discrimination of the new EORTC IPA categories for mortality. 相似文献